• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

常规血液透析过程中的磷清除:一个存在数十年的误解。

Phosphate Removal During Conventional Hemodialysis: a Decades-Old Misconception.

作者信息

Elias Rosilene M, Alvares Valeria R C, Moysés Rosa M A

机构信息

Department of Medicine, Renal Division, Universidade de São Paulo, São Paulo, Brazil.

Universidade Nove de Julho, UNINOVE, São Paulo, Brazil.

出版信息

Kidney Blood Press Res. 2018;43(1):110-114. doi: 10.1159/000487108. Epub 2018 Jan 31.

DOI:10.1159/000487108
PMID:29414834
Abstract

BACKGROUND/AIMS: Hyperphosphatemia is associated with high mortality rate in patients on dialysis. Conventional hemodialysis (HD) is a limit technique in removing phosphate (P). There is a widespread belief that P is removed mainly in the first hour of HD. The aim of this study was to certify the percentage of 1-hour removal of P as compared to the entire procedure.

METHODS

data from the first dialysis of the week of 21 patients (13 men, age 44±15 years), for 3 consecutive dialysis sessions were evaluated. Fresh dialysate samples were collected at 1 hour and at the end of the session from a partial spent dialysate collection method.

RESULTS

Pre dialysis serum P was 4.7±1.7 mg/dl. Reduction rate of serum P was 47.4 ± 14.3 and 45.1 ± 10.8% in 1- and 4-hour of HD, respectively (p=0.322). P removal was 194 (145, 242) mg in 1-hour (p<0.0001), which represents 25.0 ± 0.2% of the total removed during the entire HD. Patients with pre dialysis P ≥ 5.5mg/dl had higher P removal during HD than those with P < 5.5mg/dl [975 (587, 1354) vs. 776 (580, 784) mg, p=0.025], although the percentage of removal in 1 hour was not different from those with P < 5.5mg/d (24.9 ± 0.3 vs. 25.0 ± 0.1%, p=0.918). P removal during dialysis correlated with pre dialysis serum P (r=0.455, p=0.001), parathormone (r=0.264, p=0.037) and ultrafiltration volume (r=0.343, p=0.019).

CONCLUSION

despite the P serum concentration normalizing in the first hour of hemodialysis, the removal in the same period reaches only 25% of the entire session.

摘要

背景/目的:高磷血症与透析患者的高死亡率相关。传统血液透析(HD)在清除磷酸盐(P)方面是一种有限的技术。人们普遍认为磷主要在血液透析的第一个小时被清除。本研究的目的是确定与整个过程相比,1小时内磷的清除百分比。

方法

对21例患者(13名男性,年龄44±15岁)连续3次透析治疗中每周第一次透析的数据进行评估。采用部分用过的透析液收集方法,在1小时和透析结束时收集新鲜透析液样本。

结果

透析前血清磷为4.7±1.7mg/dl。血液透析1小时和4小时时血清磷的降低率分别为47.4±14.3%和45.1±10.8%(p=0.322)。1小时内磷清除量为194(145,242)mg(p<0.0001),占整个血液透析过程中总清除量的25.0±0.2%。透析前磷≥5.5mg/dl的患者在血液透析期间的磷清除量高于磷<5.5mg/dl的患者[975(587,1354)mg对776(580,784)mg,p=0.025],尽管1小时内的清除百分比与磷<5.5mg/dl的患者没有差异(24.9±0.3%对25.0±0.1%,p=0.918)。透析期间的磷清除与透析前血清磷(r=0.455,p=0.001)、甲状旁腺激素(r=0.264,p=0.037)和超滤量(r=0.343,p=0.019)相关。

结论

尽管血液透析第一小时血清磷浓度恢复正常,但该时段的清除量仅占整个疗程的25%。

相似文献

1
Phosphate Removal During Conventional Hemodialysis: a Decades-Old Misconception.常规血液透析过程中的磷清除:一个存在数十年的误解。
Kidney Blood Press Res. 2018;43(1):110-114. doi: 10.1159/000487108. Epub 2018 Jan 31.
2
Phosphate removal model: an observational study of low-flux dialyzers in conventional hemodialysis therapy.磷酸盐清除模型:传统血液透析治疗中低通量透析器的观察性研究
Hemodial Int. 2012 Jul;16(3):363-76. doi: 10.1111/j.1542-4758.2012.00678.x. Epub 2012 Feb 23.
3
Phosphate Removal During Long Nocturnal Hemodialysis/Hemodiafiltration: A Study With Total Dialysate Collection.长时间夜间血液透析/血液透析滤过过程中的磷清除:一项全量透析液收集研究
Ther Apher Dial. 2016 Jun;20(3):267-71. doi: 10.1111/1744-9987.12435.
4
Phosphate mass removal during hemodialysis: a comparison between eKT/V-matched conventional and extended dialysis.血液透析过程中磷酸盐质量的清除:eKT/V 匹配的常规透析与延长透析的比较。
Am J Nephrol. 2012;36(2):121-6. doi: 10.1159/000338675. Epub 2012 Jul 7.
5
Impact of convective flow on phosphorus removal in maintenance hemodialysis patients.对流对维持性血液透析患者磷清除的影响
J Ren Nutr. 2006 Jan;16(1):47-53. doi: 10.1053/j.jrn.2005.10.008.
6
[Factors which influence phosphorus removal in hemodialysis].[影响血液透析中磷清除的因素]
Nefrologia. 2007;27(1):46-52.
7
Phosphate Kinetics During Weekly Cycle of Hemodialysis Sessions: Application of Mathematical Modeling.血液透析疗程每周周期中的磷酸盐动力学:数学模型的应用
Artif Organs. 2015 Dec;39(12):1005-14. doi: 10.1111/aor.12489. Epub 2015 May 20.
8
Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.强化血液透析、矿物质和骨代谢紊乱及磷结合剂的应用。
Am J Kidney Dis. 2016 Nov;68(5S1):S24-S32. doi: 10.1053/j.ajkd.2016.05.024.
9
The impact of blood flow rate on dialysis dose and phosphate removal in hemodialysis patients.血流速率对血液透析患者透析剂量和磷清除的影响。
Saudi J Kidney Dis Transpl. 2018 Jul-Aug;29(4):872-878. doi: 10.4103/1319-2442.239654.
10
Modification and Validation of the Phosphate Removal Model: A Multicenter Study.磷酸盐去除模型的修改与验证:一项多中心研究
Kidney Blood Press Res. 2021;46(1):53-62. doi: 10.1159/000511375. Epub 2021 Jan 21.

引用本文的文献

1
Intradialytic serum phosphate variations are associated with low PTH levels.透析过程中血清磷酸盐的变化与低 PTH 水平有关。
J Nephrol. 2024 Sep;37(7):1911-1919. doi: 10.1007/s40620-024-02062-y. Epub 2024 Aug 23.
2
Phosphate Intake and Removal in Predominantly Vegetarian Patients on Twice-Weekly Hemodialysis.每周两次血液透析的主要素食患者的磷摄入与清除
Indian J Nephrol. 2022 Nov-Dec;32(6):582-587. doi: 10.4103/ijn.IJN_102_21. Epub 2022 Nov 21.
3
Phosphate-Trapping Liposomes for Long-Term Management of Hyperphosphatemia.用于高磷血症长期管理的磷酸捕获脂质体
Materials (Basel). 2022 Nov 4;15(21):7779. doi: 10.3390/ma15217779.
4
Hypophosphatemia after hemodialysis and its association with some clinical complications in patients with chronic kidney disease.血液透析后低磷血症及其与慢性肾脏病患者某些临床并发症的关联。
Caspian J Intern Med. 2022 Summer;13(3):527-532. doi: 10.22088/cjim.13.3.527.
5
EOS789, a broad-spectrum inhibitor of phosphate transport, is safe with an indication of efficacy in a phase 1b randomized crossover trial in hemodialysis patients.EOS789 是一种广谱磷酸盐转运抑制剂,在血液透析患者的 1b 期随机交叉试验中显示出疗效和安全性。
Kidney Int. 2021 May;99(5):1225-1233. doi: 10.1016/j.kint.2020.09.035. Epub 2020 Oct 31.
6
Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease.慢性肾脏病继发性甲状旁腺功能亢进症管理中的争议。
Curr Osteoporos Rep. 2019 Oct;17(5):333-342. doi: 10.1007/s11914-019-00533-x.
7
The role of phosphate-containing medications and low dietary phosphorus-protein ratio in reducing intestinal phosphorus load in patients with chronic kidney disease.磷结合药物和低膳食磷蛋白比值在降低慢性肾脏病患者肠道磷负荷中的作用。
Nutr Diabetes. 2019 Apr 3;9(1):14. doi: 10.1038/s41387-019-0080-2.